title: [An Elderly Patient with Non-Small Cell Lung Cancer Who Responded to Salvage S-1 Monotherapy after Gefitinib Therapy].
abstract: S-1 is one of the effective chemotherapy regimens for treating non-small cell lung cancer. We report of an elderly patient with non-small cell lung cancer who responded to S-1 monotherapy following gefitinib therapy. An 83-year-old woman was diagnosed with advanced adenocarcinoma of the lungs (cT3N3M1a, Stage IV). Considering her age, monotherapy with vinorelbine was administered as first-line chemotherapy. Despite the completion of four courses, she was diagnosed with progressive disease. Thereafter, after considering her status as a non-smoking woman, gefitinib was introduced as second-line chemotherapy, which resulted in significant tumor size reduction.Tumor regrowth was identified 16 months later, and gefitinib was switched to erlotinib, but the tumor kept increasing in size.S -1 monotherapy was introduced as fourth-line chemotherapy, and the tumor began to decrease in size again. A partial response was obtained after 10 months, without serious adverse effects. Gefitinib following S-1 monotherapy resulted in long-term tumor size control for a total of 27 months in an elderly patient with advanced non-small cell lung cancer.S -1 monotherapy might be one of the options for salvage therapy after gefitinib treatment becomes ineffective.
authors.affiliation: Division of Pulmonary Medicine, Dept. of Internal Medicine, National Hospital Organization Disaster Medical Center.
authors.forename: Atsuto
authors.initials: A
authors.lastname: Mouri
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Hamamoto
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Kameyama
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Ibe
authors.forename: Shinjiro
authors.initials: S
authors.lastname: Takeoka
authors.forename: Chie
authors.initials: C
authors.lastname: Honma
authors.forename: Munehisa
authors.initials: M
authors.lastname: Fukusumi
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Kamimura
mesh_terms: D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D018450:Disease Progression; D004338:Drug Combinations; D017809:Fatal Outcome; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010094:Oxonic Acid / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use; D016879:Salvage Therapy; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004338:Drug Combinations; D011799:Quinazolines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077156:Gefitinib